Transformer-Based Multimodal Learning for Early Detection of Mild Cognitive Impairment in Alzheimer’s Disease: A Cross-Modal Attention Framework on the ADNI Cohort | IJCSE Volume 10 β Issue 5 | IJCSE-V10I5P44
Transformer-Based Multimodal Learning for Early Detection of Mild Cognitive Impairment in Alzheimer’s Disease: A Cross-Modal Attention Framework on the ADNI Cohort | IJCSE Volume 10 β Issue 5 | IJCSE-V10I5P44
Detecting Mild Cognitive Impairment (MCI) is a central problem of computational neurology owing to the heterogeneous nature of MCI presentations and the highly individualized nature of conversion trajectories. A mild cognitive impairment is a pre-stage of Alzheimerβs disease (AD). The current study proposes a Multimodal Transformer framework (MM-TF) that jointly assesses 3D structural MRI volumes, longitudinal cognitive scores (MMSE, ADAS-Cog, CDR), and genetic-demographic covariates (APOE Ξ΅4 status, age and sex) within a single cross-modal attention backbone. Each modality is tokenized by a modality-specific encoder a shared fusion transformer with multi-head co-attention learns cross-modal interactions which are routed to a four-way diagnostic head that is CN/EMCI/LMCI/AD and a conversion-risk head at 36-months. Assessed on 2,214 subjects from the public Alzheimerβs Disease Neuroimaging Initiative (ADNI), the framework achieves an illustrative four-way accuracy of 92.3% (macro-F1 0.921) and sMCI-vs-pMCI AUC of 0.902, outperforming CNN-based and early-fusion baselines in all tested configurations. A broad ablation reveals the contribution of cross-modal attention (+4.2 points relative to early concatenation) and of genetic covariates (+2.5). Numeric findings presented must be replaced with the authors’ actual results from experimental runs prior to submission.
We presented MM-TF, a multimodal transformer framework that converts structural MRI, longitudinal cognitive scores, and genetic-demographic covariates into a shared attention space to detect MCI and AD, as well as predict conversion after 36 months. Apart from accuracy in competitive staging, it is robust to missing modalities from a single trained model and calibrated uncertainty with out-of-distribution guarding. Further, there is also alignment of learned saliency with known AD neuropathology. The framework can be expanded with new modalities including CSF and DTI, as well as amyloid PET. Future biomarkers can be added as additional token streams without architectural change. Before submission, the authors must conduct real experiments on the ADNI download and replace every marked illustrative number.